← Eichor
Condition: Thrombocytopenia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Thrombocytopenia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07043894Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Phase 1 · 5 location(s) · Chongqing Peg-Bio Biopharm Co., Ltd. · NCT06880081Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04518475Romiplostim for Oral TPO-RA Resistant ITP
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07612319V-IMMUNE® for Immune Thrombocytopenia
Phase 3 · 2 location(s) · On Pharma Importadora, Exportadora e Distribuidora de Medica · NCT06962631Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05214391Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Th
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07206823Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopen
Phase 2/Phase 3 · 20 location(s) · argenx · NCT07194850Single Arm Romiplostim to Prevent CIT
EARLY_Phase 1 · 2 location(s) · Children's Hospital Medical Center, Cincinnati · NCT07048249Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/Phase 2 · 45 location(s) · Eli Lilly and Company · NCT06721013Herombopag Treated T-DM1 Induced Platelet Reduction
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07257809Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
NA · 1 location(s) · Sohag University · NCT07093606French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT02877706Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · 10 location(s) · CRISPR Therapeutics AG · NCT07549698The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
NA · 7 location(s) · Yunfeng Cheng · NCT06479317Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07205861Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thromb
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05338190Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07513948Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury
NA · 1 location(s) · University of Colorado, Denver · NCT06349577Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
Phase 4 · 10 location(s) · Peking University First Hospital · NCT06722586Impact of Thrombocytopenia and Platelet Transfusions on Neonatal Bleeding and Inflammation
Phase N/A · 2 location(s) · Boston Children's Hospital · NCT03848923CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed
Phase 3 · 36 location(s) · Sanofi · NCT07007962Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
Phase 1 · 1 location(s) · Gliknik Inc. · NCT07605845
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.